Umbilical cord blood transplantation (UCBT) with reducedintensity conditioning (RIC) has been reported in older patients and/or those with comorbidities who have no suitable related or unrelated donors. [1] [2] [3] [4] However, RIC for UCBT has not yet been standardized due to a high rate of graft failure and TRM. To reduce regimen-related toxicity, non-TBI containing regimens that employ agents such as fludarabine (Flu) and either melphalan (Mel) or Bu have been attempted, but are associated with a high rate of graft failure. 5, 6 In contrast, with CBT using a conditioning regimen consisting of Flu, Mel and TBI, a high rate of TRM has been documented. 4 A less toxic conditioning regimen of sufficient intensity to achieve engraftment is therefore required. Flu/Bu-based conditioning has been reported to be less toxic than Flu/Mel-based conditioning. 7 Barker et al. 2 reported a high rate of graft failure for Flu/oral Bu with 200 cGy TBI. In addition, unlike oral Bu, i.v. Bu is not influenced by variable dose-to-dose bioavailability 8 and does not depend on intestinal absorption, which can be disrupted by gastrointestinal complications. It has been suggested that a high Bu concentration is associated with an increased risk of TRM. 9 Conversely, a low area under the curve (AUC) regarding Bu level could increase the risk of graft rejection and/or disease relapse. An adequate plasma Bu concentration can lead to sufficient immunosuppression that facilitates engraftment, with a lower rate of disease relapse and less toxicity. We therefore hypothesized that Flu TBI combined with an increased dose of i.v. Bu rather than oral Bu might be a more optimal regimen.
We retrospectively analyzed all patients at our institute who had undergone UCBT with Flu, i.v. Bu, and low-dose TBI between March 2005 and June 2011. Ten patients with a median age of 61 (range 40-68) were evaluated ( Table 1 ). The preparative conditioning regimen consisted of Flu 30 mg/m 2 /day on days − 9 to − 4 (total dose, 180 mg/m 2 ), i.v. Bu 0.8 mg/kg every 12 h on days − 9 to − 5 (total dose, 8 mg/kg) and 400 cGy TBI in two fractions on day − 1. In all patients, a single cord unit was transplanted. In most patients, CYA (15 mg/kg twice a day from day − 1) and short-term MTX (10 mg/m 2 on day 1, 7 mg/m 2 on day 3 and 7 mg/m 2 on day 5) were used as GVHD prophylaxis. This study was approved by the Institutional Review Board.
The median follow-up time of survivors was 5.2 years (range 1.7-6.3). In two patients who had active disease and infection at the time of transplantation, engraftment could not be evaluated due to early death at day 9 or day 14 after UCBT without hematopoietic recovery. Of the remaining eight patients, seven achieved neutrophil engraftment after a median duration of 22 days (range 13-31). Platelet recovery was documented in six patients after a median duration of 53 days (range 24-234). In all evaluable patients, complete donor T-cell chimerism in the peripheral blood, as assessed by CD3+ cells, was confirmed at day 30 and was sustained at days 60 and 90. Two of the three patients (Nos. 6 and 8) had active disease and infection at the start of conditioning. The one patient in our study (No. 9) in whom neutrophil recovery was not observed more than 28 days after UCBT died on day 34 from pneumonia and alveolar hemorrhage due to Stenotrophomonas maltophilia. The same pathogen was also detected in blood culture. TRM and relapse rate at 5 years were 10% and 50%, respectively. Overall survival was 40% at 5 years.
Although oral mucositis was the most frequent regimen-related toxicity, diarrhea of more than grade 2 was seen in just one patient (Table 2) . Grade III to IV gut GVHD was also only observed in one patient (Table 1 ). In addition, no patient developed grade 4 toxicity in any organ. Veno-occlusive disease was also not observed in any patient. In this study, all evaluable patients with the exception of one achieved engraftment and complete T-cell donor chimerism by day 30. Three of four patients (75%) in CR or PR at the time of UCBT have remained in long-term remission (Table 1) .
Barker et al. 2 reported on a large pilot trial of UCBT with Flu, TBI (200 cGy) and either oral Bu (8 mg/kg) or CY (50 mg/kg). In that study, the CY group had a better outcome than the Bu group, with only 76% sustaining engraftment in the Bu group. The Minnesota group reported a 92% neutrophil engraftment rate with the use of Flu, CY and TBI for conditioning for UCBT. 3 However, most of these patients received two cord units, which is still not permissible in many countries. From the limited data available from their study related to transplantation of a single cord unit, the relapse rate at 3 years was high, at 41%. Non-myeloablative conditioning with/ without the use of antithymocyte globulin might be associated with an increased risk of relapse. Uchida et al. 4 reported a conditioning regimen consisting of Flu (125 mg/m 2 ), Mel (80 mg/ m 2 ) and TBI 400 cGy, for transplantation of a single unit of cord blood. TRM was 45% and OS was 23% at 2 years. Severe gastrointestinal mucositis induced by the combination of Mel and TBI possibly caused severe gut infection and GVHD, which may have contributed to the high TRM.
In our study, Grade III to IV gut GVHD was observed in just one patient, suggesting the possibility that the lower gastrointestinal toxicity of this conditioning regimen could decrease the incidence of not only severe gut infection but also GVHD; a 10% rate of TRM at 5 years appears to be an acceptable outcome compared with the previous report. 10 Despite the small sample size of our study, a myeloablative dose of i.v. Bu (8 mg/kg) and 400 cGy TBI could be an option in older patients and/or those with comorbidities.
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